Guanfacine to Treat Borderline Personality Disorder
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00358969 |
Recruitment Status : Unknown
Verified July 2006 by Bronx VA Medical Center.
Recruitment status was: Recruiting
First Posted : August 1, 2006
Last Update Posted : August 1, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Borderline Personality Disorder | Drug: guanfacine (Tenex) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Guanfacine in the Treatment of Borderline Personality Disorder |
Study Start Date : | July 2006 |

- measures of impulsive aggression
- measures of affective disturbance
- measures of social and occupational functioning
- measures of overall clinical status

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: This study includes men and women between the ages of 18 and 55 who meet criteria for borderline personality disorder with impulsive aggression.
Exclusion Criteria: Subjects must not currently be taking any psychiatric medications. Subjects must not meet criteria for current substance dependence, current major depression, bipolar disorder, or schizophrenia-spectrum disorders.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00358969
Contact: Emily Hart | (212) 241-4459 | mpgroup@mssm.edu | |
Contact: David Meyerson | (212) 241-9734 | david.meyerson@mssm.edu |
United States, New York | |
Mount Sinai Hospital - Mood & Personality Research Group | Recruiting |
New York, New York, United States, 10029 |
Principal Investigator: | Antonia S. New, M.D. | Icahn School of Medicine at Mount Sinai |
ClinicalTrials.gov Identifier: | NCT00358969 |
Other Study ID Numbers: |
GCO 06-0518 |
First Posted: | August 1, 2006 Key Record Dates |
Last Update Posted: | August 1, 2006 |
Last Verified: | July 2006 |
borderline personality disorder guanfacine impulsivity aggression affective instability |
Disease Personality Disorders Borderline Personality Disorder Pathologic Processes Mental Disorders Guanfacine Antihypertensive Agents |
Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |